Brigatinib (Alunbrig) for Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer - Details


( Last Updated : May 6, 2021)
Generic Name:
Brigatinib
Project Status:
Complete
Therapeutic Area:
(ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
Manufacturer:
Takeda Canada Inc.
Brand Name:
Alunbrig
Project Line:
Reimbursement Review
Project Number:
PC0230-000
NOC Date:

Details


Tumour Type:
Lung
Indications:
Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
Funding Request:
For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor.
Review Status:
Notification to Implement Issued
Pre Noc Submission:
Yes
Sponsor:
Takeda Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.